Angiotensin II and vascular injury

Current Hypertension Reports

Volumn 16, Issue 6, 2014, Pages

  Montezano, Augusto C ^a   Nguyen Dinh Cat, Aurelie ^a   Rios, Francisco J ^a   Touyz, Rhian M ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Angiotensin receptors; Atherosclerosis; Calcification; Inflammation; Oxidative stress; Signal transduction; Vascular remodelling

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BLOOD VESSEL INJURY; CARDIOVASCULAR SYSTEM; INFLAMMATION; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CARDIOVASCULAR DISEASE; DRUG EFFECTS; HUMAN; HYPERTENSION; METABOLISM; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE; VASCULAR SYSTEM INJURIES;

ANGIOTENSIN II; ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; MUSCLE, SMOOTH, VASCULAR; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION; VASCULAR REMODELING; VASCULAR SYSTEM INJURIES;

EID: 84901736495     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-014-0431-2     Document Type: Review

References (154)

1. Schiffrin EL, Touyz RM. From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol. 2004;287(2):H435-46. (Pubitemid 38960790)
2. Touyz RM. The role of angiotensin II in regulating vascular structural and functional changes in hypertension. Curr Hypertens Rep. 2003;5(2):155-64. (Pubitemid 38898946)
3. Aroor AR, Demarco VG, Jia G, Sun Z, Nistala R, Meininger GA, et al. The role of tissue renin-angiotensin-aldosterone system in the development of endothelial dysfunction and arterial stiffness. Front Endocrinol. 2013;4:161-8.
4. Ferrario CM. New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism. Hypertension. 2010;55(2):445-52.
5. Ferrario CM, Ahmad S, Nagata S, Simington SW, Varagic J, Kon N, et al. An evolving story of angiotensin-II-forming pathways in rodents and humans. Clin Sci (Lond). 2014;126(7):461-9.
6. Bader M. Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Annu Rev Pharmacol Toxicol. 2010;50:439-65.
7. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med. 1994;330:1431-8. (Pubitemid 24139238)
8. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension. 2001;38:581-7.
9. Martinez-Lemus LA, Hill MA, Meininger GA. The plastic nature of the vascular wall: a continuum of remodeling events contributing to control of arteriolar diameter and structure. Physiology. 2009;24:45-57.
10. Harrison DG, Vinh A, Lob H, Madhur MS. Role of the adaptive immune system in hypertension. Curr Opin Pharmacol. 2010;10(2):203-7.
11. Thatcher S. The adipose renin-angiotensin system: role in cardiovascular disease. Mol Cell Endocrinol. 2009;302(2):111-7.
12. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204(10):2449-60. (Pubitemid 47529329)
13. Prieto MC, Gonzalez AA, Navar LG. Evolving concepts on regulation and function of renin in distal nephron. Pflugers Arch. 2013;465(1):121-32.
14. Cassis LA. Local adipose tissue renin-angiotensin system. Curr Hypertens Rep. 2008;10(2):93-8.
15. Miyazaki M, Takai S. Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase. J Pharmacol Sci. 2006;100(5):391-7. (Pubitemid 44609530)
16. Reudelhuber TL. Prorenin, Renin, and their receptor: moving targets. Hypertension. 2010;55(5):1071-107.
17. Danser AJ, Nguyen G. The Renin Academy Summit: advancing the understanding of renin science. J Renin-Angiotensin-Aldosterone Syst. 2008;9(2):119-23. (Pubitemid 351998221)
18. Nguyen G, Muller DN. The biology of the (pro)renin receptor. J Am Soc Nephrol. 2010;21(1):8-23.
19. Nguyen G. The (pro)renin receptor in health and disease. Ann Med. 2010;42(1):13-8.
20. Hitom H, Liu G, Nishiyama A. Role of (pro)renin receptor in cardiovascular cells from the aspect of signaling. Front Biosci. 2010;2:1246-9.
21. Advani A, Kelly DJ, Cox AJ,White KE, Advani SL, Thai K, et al. The (pro)renin receptor: site-specific and functional linkage to the vacuolar H+ -ATPase in the kidney. Hypertension. 2009;54:261-9.
22. Cousin C, Bracquart D, Contrepas A, Nguyen G. Potential role of the (pro)renin receptor in cardiovascular and kidney diseases. J Nephrol. 2010;23:508-13.
23. Xia H, Lazartigues E. Angiotensin-converting enzyme 2: central regulator for cardiovascular function. Curr Hypertens Rep. 2010;12(3):170-5.
24. Bader M. ACE2, angiotensin-(1-7), andMas: the other side of the coin. Pflugers Arch. 2013;465(1):79-85.
25. Shaltout HA. Alterations in circulatory and renal angiotensin-converting enzyme and angiotensin-converting enzyme 2 in fetal programmed hypertension. Hypertension. 2009;53(2):404-8.
26. Fraga-Silva RA, Savergnini SQ,Montecucco F,Nencioni A, Caffa I, Soncini D, et al. Treatment with Angiotensin-(1-7) reduces inflammation in carotid atherosclerotic plaques. Thromb Haemost. 2014;111(4):736-47.
27. Imai Y. Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. Circ J. 2010;74(3):405-10.
28. Ferrario CM, Iyer SN. Angiotensin-(1-7): a bioactive fragment of the renin-angiotensin system. Regul Pept. 1998;78(1-3):13-8. (Pubitemid 28561512)
29. Santiago NM. Lifetime overproduction of circulating Angiotensin-(1-7) attenuates deoxycorticosterone acetate-salt hypertension-induced cardiac dysfunction and remodeling. Hypertension. 2010;55(4):889-96.
30. Cangussu LM. Angiotensin-(1-7) antagonist, A-779, microinjection into the caudal ventrolateral medulla of renovascular hypertensive rats restores baroreflex bradycardia. Peptides. 2009;30(10):1921-7.
31. Silva DM. Evidence for a new angiotensin-(1-7) receptor subtype in the aorta of Sprague-Dawley rats. Peptides. 2007;28(3):702-7. (Pubitemid 46204993)
32. Santos RA, Ferreira AJ, Simões E, Silva AC. Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis. Exp Physiol. 2008;93(5):519-27. (Pubitemid 351595060)
33. Sampaio WO, Souza dos Santos RA, Faria-Silva R, da Mata Machado LT, Schiffrin EL, Touyz RM. Angiotensin-(1-7) counter-regulates angiotensin II signaling in human endothelial cells. Hypertension. 2007;50(6):1093-8. (Pubitemid 350172931)
34. Gwathmey TM, Pendergrass KD, Reid SD, Rose JC, Diz DI, Chappell MC. Angiotensin-(1-7)-angiotensin-converting enzyme 2 attenuates reactive oxygen species formation to angiotensin II within the cell nucleus. Hypertension. 2010;55(1):66-171.
35. Santos RA, Frézard F, Ferreira AJ. Angiotensin-(1-7): blood, heart, and blood vessels. Curr Med Chem Cardiovasc Hematol Agents. 2005;3(4):383-91. (Pubitemid 41264275)
36. Reaux A, Fournie-ZaluskiMC, Llorens-Cortes C.Angiotensin III: a central regulator of vasopressin release and blood pressure. Trends Endocrinol Metab. 2001;12(4):157-62. (Pubitemid 33713556)
37. Yang R, Walther T, Gembardt F, Smolders I, Vanderheyden P, Albiston AL, et al. Renal vasoconstrictor and pressor responses to angiotensin IV in mice are AT1a-receptor mediated. J Hypertens. 2010;28(3):487-94.
38. Ferreira PM, Souza Dos Santos RA, Campagnole-Santos MJ. Angiotensin-(3-7) pressor effect at the rostral ventrolateral medulla. Regul Pept. 2007;141(1-3):168-74. (Pubitemid 46482697)
39. OcaranzaMP, Jalil JE. Protective role of the ACE2/Ang-(1-9) axis in cardiovascular remodeling. Int J Hypertens. 2012;2012:594-361.
40. Ahmad S, Wei CC, Tallaj J, Dell'Italia LJ, Moniwa N, Varagic J, et al. Chymase mediates angiotensin-(1-12) metabolism in normal human hearts. J Am Soc Hypertens. 2013;7(2):128-36.
41. Vaajanen A, Luhtala S, Oksala O, Vapaatalo H. Does the renin-angiotensin system also regulate intra-ocular pressure? Ann Med. 2008;40(6):418-27.
42. Wilkinson-Berka JL, Agrotis A, Deliyanti D. The retinal renin-angiotensin system: roles of angiotensin II and aldosterone. Peptides. 2012;36(1):142-50.
43. Kumar R, Singh VP, Baker KM. The intracellular renin-angiotensin system in the heart. Curr Hypertens Rep. 2009;11(2):104-10.
44. deGasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology XXII. The angiotension II receptors. Pharmacol Rev. 2000;52:415-72.
45. Namsolleck P, Recarti C, Foulquier S, Steckelings UM, Unger T. AT(2) receptor and tissue injury: therapeutic implications. Curr Hypertens Rep. 2014;16(2):416.
46. Carey RM, Padia SH. Role of angiotensin AT(2) receptors in natriuresis: Intrarenal mechanisms and therapeutic potential. Clin Exp Pharmacol Physiol. 2013;40(8):527-34.
47. Levy BI. How to explain the differences between renin-angiotensin system modulators. Am J Hypertens. 2005;18:134S-41S. (Pubitemid 41206570)
48. Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S. Angiotensin II signal transduction through theAT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond). 2007;112(8):417-28. (Pubitemid 46587457)
49. Matsubara H. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal disease. Circ Res. 1998;83:1182-91. (Pubitemid 29006033)
50. Steckelings UM, Kaschina E, Unger. The AT2 receptor-A matter of love or hate. Peptides. 2005;26:1401-9. (Pubitemid 41021474)
51. Tamura K, Wakui H, Maeda A, Dejima T, Ohsawa M, Azushima K, et al. The physiology and pathophysiology of a novel angiotensin receptor-binding protein ATRAP/Agtrap. Curr Pharm Des. 2013;19(17):3043-8.
52. Wakui H, Dejima T, Tamura K, Uneda K, Azuma K, Maeda A, et al. Activation of angiotensin II type 1 receptor-associated protein exerts an inhibitory effect on vascular hypertrophy and oxidative stress in angiotensin II-mediated hypertension. Cardiovasc Res. 2013;100(3):511-9.
53. Oppermann M, Gess B, Schweda F, Castrop H. Atrap deficiency increases arterial blood pressure and plasma volume. J Am Soc Nephrol. 2010;21(3):468-77.
54. Mogi M, Iwai M, Horiuchi M. Emerging concepts of regulation of angiotensin II receptors: new players and targets for traditional receptors. Arterioscler Thromb Vasc Biol. 2007;27(12):2532-9. (Pubitemid 350158902)
55. Nouet S, Amzallag N. Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP. J Biol Chem. 2004;279:28989-97. (Pubitemid 38915768)
56. Di Benedetto M. Structural organization and expression of human MTUS1, a candidate 8p22 tumor suppressor gene encoding a family of angiotensin II AT2 receptor-interacting proteins, ATIP. Gene. 2006;380(2):127-36. (Pubitemid 44363148)
57. Henrion D, Kubis N, Lévy BI. Physiological and pathophysiological functions of the AT2 subtype receptor of angiotensin II - From large arteries to the microcirculation. Hypertension. 2001;38:1150-7. (Pubitemid 34252821)
58. Akishita M. Inflammation influences vascular remodeling through AT2 receptor expression and signaling. Physiol Genomics. 2000;2:13-20.
59. Touyz RM, He G, Deng LY, Schiffrin EL. Role of extracellular signal-regulated kinases in angiotensin II-Stimulated contraction of smooth muscle cells from human resistance arteries. Circulation. 1999;99:392-9. (Pubitemid 29051265)
60. Xi XP. Central role of the MAPK pathway in Ang II-mediated DNA synthesis and migration in rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999;19:73-82.
61. Eguchi S, Inagami T. Signal transduction of angiotensin II type 1 receptor through receptor tyrosine kinase. Regul Pept. 2000;91:13-20.
62. Montezano AC, Callera GE, Yogi A, He Y, Tostes RC, He G, et al. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol. 2008;28(8):1511-8.
63. Touyz RM, Schiffrin EL. Role of calcium influx and intracellular calcium stores in angiotensin II-mediated calcium hyper-responsiveness in smooth muscle from spontaneously hypertensive rats. J Hypertens. 1997;15:1431-9. (Pubitemid 28039571)
64. Touyz RM, Yao G, Schiffrin EL. c-Src induces phosphorylation and translocation of p47phox - Role in superoxide generation by angiotensin II in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003;23:981-7. (Pubitemid 36717143)
65. Callera GE, Yogi A, Briones AM, Montezano AC, He Y, Tostes RC, et al. Vascular proinflammatory responses by aldosterone are mediated via c-Src trafficking to cholesterol-rich microdomains: role of PDGFR. Cardiovasc Res. 2011;91(4):720-31.
66. Touyz RM. Increased angiotensin II-mediated Src signaling via epidermal growth factor receptor transactivation is associated with decreased c-terminal Src kinase activity in vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension. 2002;39:479-85. (Pubitemid 34165169)
67. Touyz RM. Src is an important mediator of extracellular signal-regulated kinase 1/2-dependent growth signaling by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients. Hypertension. 2001;38:56-64. (Pubitemid 34224771)
68. Saito Y, Berk BC. Transactivation: a novel signaling pathway from angiotensin II to tyrosine kinase receptors. J Mol Cell Cardiol. 2001;33:3-7. (Pubitemid 32127779)
69. Burger D, Montezano AC, Nishigaki N, He Y, Carter A, Touyz RM. Endothelial microparticle formation by angiotensin II is mediated via Ang II receptor type I/NADPH oxidase/ Rho kinase pathways targeted to lipid rafts. Arterioscler Thromb Vasc Biol. 2011;31(8):1898-907.
70. Ohtsu H, Dempsey PJ, Frank GD, Brailoiu E, Higuchi S, Suzuki H, et al. ADAM17 mediates epidermal growth factor receptor transactivation and vascular smooth muscle cell hypertrophy induced by angiotensin II. Arterioscler Thromb Vasc Biol. 2006;26(9):e133-7. (Pubitemid 44253770)
71. Loirand G, Pacaud P. The role of Rho protein signaling in hypertension. Nat Rev Cardiol. 2010;7(11):637-47.
72. Uehata M, Ishizaki T, Satoh H. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389(6654):990-4. (Pubitemid 27485693)
73. Guilluy C, Bregeon J, Tourmaniantz G. The Rho exchange factor Arhgef1mediates the effects of angiotensin II on vascular tone and blood pressure. Nat Med. 2010;16:183-90.
74. Bregeon J, Loirand G, Pacaud P. Angiotensin II induces RhoA activation through SHP2-dependent dephosphorylation of the RhoGAP p190A in vascular smooth muscle cells. Am J Physiol Cell Physiol. 2009;297(5):C1062-70.
75. Cario-Toumaniantz C, Ferland-McCollough D, Chadeuf G, Toumaniantz G, Rodriguez M, Galizzi JP, et al. RhoA guanine exchange factor expression profile in arteries: evidence for a Rho kinase-dependent negative feedback in angiotensin II-dependent hypertension. Am J Physiol Cell Physiol. 2012;302:C1394-404.
76. Kobayashi N, Nakano S, Mita S, Kobayashi T, Honda T, Tsubokou Y, et al. Involvement of Rho-kinase pathway for angiotensin II-induced plasminogen activator inhibitor-1 gene expression and cardiovascular remodeling in hypertensive rats. J Pharmacol Exp Ther. 2002;301:459-66. (Pubitemid 34429955)
77. Touyz RM. Reactive oxygen species and angiotensin II signaling in vascular cells - implications in cardiovascular disease. Braz J Med Biol Res. 2004;37(8):1263-73. (Pubitemid 39172561)
78. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension. 2003;42:1075-81. (Pubitemid 37549058)
79. Touyz RM, Briones AM, Sedeek M, Burger D, Montezano AC. NOX isoforms and reactive oxygen species in vascular health. Mol Interv. 2011;11(1):27-35.
80. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol. 2003;285(2):R277-97. (Pubitemid 36898897)
81. Rey FE, Pagano PJ. The reactive adventitia: fibroblast oxidase in vascular function. Arterioscler Thromb Vasc Biol. 2002;22(12):1962-71. (Pubitemid 36025200)
82. Montezano AC, Touyz RM. Molecular mechanisms of hypertension-reactive oxygen species and antioxidants: a basic science update for the clinician. Can J Cardiol. 2012;28(3):288-95.
83. Griendling KK. Novel NAD(P)H oxidases in the cardiovascular system. Heart. 2004;90(5):491-3. (Pubitemid 38530160)
84. Briones AM, Touyz RM. Oxidative stress and hypertension: current concepts. Curr Hypertens Rep. 2010;12(2):135-42.
85. Gray SP, Di Marco E, Okabe J, Szyndralewiez C, Heitz F, Montezano AC, et al. NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. Circulation. 2013;127(18):1888-902.
86. Nguyen Dinh Cat A, Montezano AC, Burger D, Touyz RM. Angiotensin II, NADPH oxidase, and redox signaling in the vasculature. Antioxid Redox Signal. 2013;19(10):1110-20.
87. Schramm A, Matusik P, Osmenda G, Guzik TJ. Targeting NADPH oxidases in vascular pharmacology. Vasc Pharmacol. 2012;56(5-6):216-31.
88. Montezano AC, Burger D, Paravicini TM, Chignalia AZ, Yusuf H, AlmasriM, et al. Nicotinamide adenine dinucleotide phosphate reduced oxidase 5 (Nox5) regulation by angiotensin II and endothelin-1 is mediated via calcium/calmodulin-dependent, rac-1-independent pathways in human endothelial cells. Circ Res. 2010;106(8):1363-73.
89. Holterman CE, Thibodeau JF, Towaij C, Gutsol A, Montezano AC, Parks RJ, et al. Nephropathy and elevated bp in mice with podocyte-specific NADPH oxidase 5 expression. J Am Soc Nephrol. 2013;25:784-97.
90. Montezano AC, Touyz RM. Reactive oxygen species, vascular Noxs, and hypertension: focus on translational and clinical research. Antioxid Redox Signal. 2014;20(1):164-82.
91. Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, et al. Expression of a gp91phox-containing leukocyte-type NADPH oxidase in human vascular smooth muscle cells - modulation by Ang II. Circ Res. 2006;90:1205-13.
92. .• Paravicini TM, Montezano AC, Yusuf H. Touyz RM activation of vascular p38MAPK by mechanical stretch is independent of c-Src and NADPH oxidase: influence of hypertension and angiotensin II. J Am Soc Hypertens. 2012;6(3):169-78. This study clearly identifies differential mechanisms whereby Ang II and blood pressure influence mechanosensitive signaling in vascular smooth muscle cells.
93. Touyz RM, Schiffrin EL. Ang II-stimulated superoxide production is mediated via phospholipase D in human vascular smooth muscle cells. Hypertension. 1999;34(4):976-82. (Pubitemid 29501333)
94. Touyz RM, Schiffrin EL. Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. J Hypertens. 2001;19:1245-54. (Pubitemid 32595280)
95. Touyz RM. Oxidative stress and vascular damage in hypertension. Curr Hypertens Rep. 2001;2:98-105.
96. Petrovič D. Association of the -262C/T polymorphism in the catalase gene promoter and the C242T polymorphism of the NADPH oxidase P22phox gene with essential arterial hypertension in patients with diabetes mellitus type 2. Clin Exp Hypertens. 2014;36(1):36-40.
97. Virdis A, Neves MF, Amiri F, Touyz RM, Schiffrin EL. Role of NAD(P)H oxidase on vascular alterations in angiotensin II-infused mice. J Hypertens. 2004;22(3):535-42. (Pubitemid 38368487)
98. Chiarugi P, Cirri P. Redox regulation of protein tyrosine phosphatases during receptor tyrosine kinase signal transduction. Trends Biochem Sci. 2003;28:509-14. (Pubitemid 38340416)
99. Nathan C. Specificity of a third kind: reactive oxygen and nitrogen intermediates in cell signaling. J Clin Invest. 2003;111:769-78. (Pubitemid 37074948)
100. Torres M, Forman HJ. Redox signaling and the MAP kinase pathways. Biofactors. 2003;17:287-96. (Pubitemid 37267162)
101. Tabet F, Schiffrin EL, Callera GE, He Y, Yao G, Ostman A, et al. Redox-sensitive signaling by angiotensin II involves oxidative inactivation and blunted phosphorylation of protein tyrosine phosphatase SHP-2 in vascular smooth muscle cells from SHR. Circ Res. 2008;103(2):149-58.
102. .• SedeekM, Gutsol A,Montezano AC, Burger D, Nguyen Dinh Cat A, Kennedy CR, et al. Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. Clin Sci (Lond). 2013;124(3):191-202. An in vivo study demonstrating that an orally active inhibitor of Nox1 and Nox4 ameliorates development of nephropathy in a model of diabetes, indicating a role for Nox1/4-derived reactive oxygen in diabetic nephropathy.
103. Dohi Y. Candesartan reduces oxidative stress and inflammation in patients with essential hypertension. Hypertens Res. 2003;26:691-7. (Pubitemid 37258655)
104. Kamiyama M, Urushihara M, Morikawa T, Konishi Y, Imanishi M, Nishiyama A, et al. Oxidative stress/angiotensinogen/reninangiotensin systemaxis in patients with diabetic nephropathy. Int J Mol Sci. 2013;14(11):23045-62.
105. Lacolley P, Regnault V, Nicoletti A, Li Z, Michel JB. The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc Res. 2012;95(2):194-204.
106. Savoia C, Burger D, Nishigaki N, Montezano A, Touyz RM. Angiotensin II and the vascular phenotype in hypertension. Expert Rev Mol Med. 2011;13:e11.
107. Albinsson S, SessaWC. Can microRNAs control vascular smooth muscle phenotypicmodulation and the response to injury? Physiol Genomics. 2011;43(10):529-33.
108. Tayebjee MH, MacFadyen RJ, Lip GY. Extracellular matrix biology: a new frontier in linking the pathology and therapy of hypertension? J Hypertens. 2003;21:2211-8. (Pubitemid 38293553)
109. Delva P. Collagen I, and III mRNA gene expression and cell growth potential of skin fibroblasts in patients with essential hypertension. J Hypertens. 2002;20:1393-9. (Pubitemid 34925684)
110. Castro MM, Rizzi E, Prado CM, Rossi MA, Tanus-Santos JE, Gerlach RF. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol. 2010;29(3):194-201.
111. Satoh C. Role of endogenous angiotensin II in the increased expression of growth factors in vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2001;37(1):108-18. (Pubitemid 32012937)
112. Bobik A. Hypertension, transforming growth factor-β, angiotensin II and kidney disease. J Hypertens. 2004;22(7):1265-7. (Pubitemid 38888070)
113. Bruder-Nascimento T, Chinnasamy P, Riascos-Bernal DF, Cau SB, Callera GE, Touyz RM, et al. Angiotensin II induces Fat1 expression/activation and vascular smooth muscle cell migration via Nox1-dependent reactive oxygen species generation. J Mol Cell Cardiol. 2014;66:18-26.
114. Viel EC, Lemarié CA, Benkirane K, Paradis P, Schiffrin EL. Immune regulation and vascular inflammation in genetic hypertension. Am J Physiol Heart Circ Physiol. 2010;298(3):H938-44.
115. Zhao Q, Ishibashi M, Hiasa K, Tan C, Takeshita A, Egashira K. Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension. 2004;44(3):264-70. (Pubitemid 39172204)
116. .• Kasal DA, Barhoumi T, Li MW, Yamamoto N, Zdanovich E, Rehman A, et al. T Regulatory Lymphocytes Prevent Aldosterone-Induced Vascular Injury. Hypertension. 2012;59:324-30. An elegant study showing that adoptive transfer of T regulatory lymphocytes ameliorates vascular injury in mice infused with aldosterone, supporting a role for innate and adaptive immunity in vascular damage associated with activation of the renin angiotensin aldosterone system.
117. Marvar PJ, Thabet SR, Guzik TJ, Lob HE, McCann LA, Weyand C, et al. Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension. Circ Res. 2010;107(2):263-70.
118. Hoch NE, Guzik TJ, Chen W, Deans T, Maalouf SA, Gratze P, et al. Regulation of T-cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol. 2009;296(2):R208-16.
119. Suematsu M. The inflammatory aspect of the microcirculation in hypertension: oxidative stress, leukocytes/endothelial interaction, apoptosis. Microcirculation. 2002;9:259-76. (Pubitemid 135685862)
120. Wu L, Iwai M, Nakagami H. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation. 2001;104:2716-21. (Pubitemid 33108140)
121. Diep QN, Amiri F, Touyz RM, Cohn JS, Endemann D, Neves MF, et al. PPARa activator effects on Ang II-induced vascular oxidative stress and inflammation. Hypertension. 2002;40:866-71. (Pubitemid 35434908)
122. Sigmund CD. Endothelial and vascular muscle PPARgamma in arterial pressure regulation: lessons from genetic interference and deficiency. Hypertension. 2010;55(2):437-44.
123. Tham DM. Angiotensin II, is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics. 2002;11:21-30. (Pubitemid 37128718)
124. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation. 2007;116(1):85-97. (Pubitemid 47016250)
125. Anand DV, Lim E, Darko D, Bassett P, Hopkins D, Lipkin D, et al. Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers. J Am Coll Cardiol. 2007;50(23):2218-25. (Pubitemid 350166815)
126. Ng K, Hildreth CM, Avolio AP, Phillips JK. Angiotensin-converting enzyme inhibitor limits pulse-wave velocity and aortic calcification in a rat model of cystic renal disease. Am J Physiol Renal Physiol. 2011;301(5):F959-66.
127. Karwowski W, Naumnik B, Szczepański M. Myśliwiec The mechanism of vascular calcification - a systematic review. Med Sci Monit. 2012;18:1-11.
128. Tyson KL, Reynolds JL, McNair R, Zhang Q, Weissberg PL, Shanahan CM. Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification. Arterioscler Thromb Vasc Biol. 2003;23:489-94. (Pubitemid 36337227)
129. Huybers S, Bindels RJ. Vascular calcification in chronic kidney disease: new developments in drug therapy. Kidney Int. 2007;72:663-5. (Pubitemid 47373798)
130. Li X, Giachelli CM. Sodium-dependent phosphate cotransporters and vascular calcification. Curr Opin Nephrol Hypertens. 2007;16:325-8. (Pubitemid 46944330)
131. Li X, Yang HY, Giachelli CM. BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis. 2008;199:271-7.
132. Freedman BI, Bowden DW, Ziegler JT, Langefeld CD, Lehtinen AB, Rudock ME, et al. Bone morphogenetic protein 7 (BMP7) gene polymorphisms are associated with inverse relationships between vascular calcification and BMD: the Diabetes Heart Study. J Bone Miner Res. 2009;24:1719-27.
133. ScatenaM, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol. 2007;27:2302-9. (Pubitemid 350203943)
134. .• Osako MK, Nakagami H, Shimamura M, Koriyama H, Nakagami F, Shimizu H, et al. Cross-Talk of receptor activator of nuclear factor-κB ligand signaling with renin-angiotensin system in vascular calcification. Arterioscler Thromb Vasc Biol. 2013;33:1287-96. In vitro and in vivo studies demonstrate that Ang II induces vascular calcification through pathways that involve receptor activator of nuclear factor-κB ligand (RANKL) and that RANKL itself influences the RAS. These data indicate a circuitous interaction between these systems that amplifies atherogenesis and vascular calcification.
135. Montezano AC, Zimmerman D, Yusuf H, Burger D, Chignalia AZ, Wadhera V, et al. Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. Hypertension. 2010;56(3):453-62.
136. He Y, Yao G, Savoia C, Touyz RM. Transient receptor potential melastatin 7 ion channels regulate magnesium homeostasis in vascular smooth muscle cells: role of angiotensin II. Circ Res. 2005;96(2):207-15. (Pubitemid 40209368)
137. .• Jia G, Stormont RM, Gangahar DM, Agrawal DK. Role of matrix Gla protein in angiotensin II-induced exacerbation of vascular calcification. Am J Physiol Heart Circ Physiol. 2012;303(5):H523-32. Demonstration that Ang II influences vascular calcification through processes that interfere with the natural calcification inhibitor, matrix Gla protein and activation of the transcription factors, runt-related transcription factor 2 and NF-κB.
138. Sui YB, Chang JR, Chen WJ, Zhao L, Zhang BH, Yu YR, et al. Angiotensin-(1-7) inhibits vascular calcification in rats. Peptides. 2013;42:25-34.
139. Virmani R, Robinowitz M, Geer JC, Breslin PP, Beyer JC, McAllister HA. Coronary artery atherosclerosis revisited in Korean war combat casualties. Arch Pathol Lab Med. 1987;111(10):972-6. (Pubitemid 17145651)
140. Steinbrecher UP, Parthasarathy S, Leake DS. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of lowdensity lipoprotein phospholipids. Proc Natl Acad Sci U S A. 1984;81:3883-7. (Pubitemid 14087823)
141. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;16:1832-44. (Pubitemid 350287108)
142. Nicholson AC, Frieda S, Pearce A, Silverstein RL. Oxidized LDL binds to CD36 on human monocyte-derived macrophages and transfected cell lines. Evidence implicating the lipid moiety of the lipoprotein as the binding site. Arterioscler Thromb Vasc Biol. 1995;15(2):269-75.
143. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 1998;93(2):229-40. (Pubitemid 28180856)
144. Rios FJ, Ferracini M, Pecenin M, Koga MM, Wang Y, Ketelhuth DF, et al. Uptake of oxLDL and IL-10 production bymacrophages requires PAFR and CD36 recruitment into the same lipid rafts. PLoS ONE. 2013;8(10):e76893.
145. Rios FJ, Koga MM, Pecenin M, Ferracini M, Gidlund M, Jancar S. Oxidized LDL induces alternative macrophage phenotype through activation of CD36 and PAFR. Mediat Inflamm. 2013;2013:198 - 3.
146. Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity. 2013;38(6):1092-104.
147. .• Kiyan Y, Tkachuk S, Hilfiker-Kleiner D, Haller H, Fuhrman B, Dumler I. oxLDL induces inflammatory responses in vascular smooth muscle cells via urokinase receptor association with CD36 and TLR4. J Mol Cell Cardiol. 2014;66:72-82. This study elucidates a novel mechanism contributing to vascular inflammation through the urokinase receptor, which responds to endogenous atherogenic ligands, such as oxLDL, impacting on CD36 and TLR4 function.
148. .• Wang YS, Wang HY, Liao YC, Tsai PC, Chen KC, Cheng HY, et al. MicroRNA-195 regulates vascular smooth muscle cell phenotype and prevents neointimal formation. Cardiovasc Res. 2012;95(4):517-26. This interesting study demonstrates that in vascular smooth muscle cells, microRNA-195 reduces proliferation, migration, and synthesis of IL-1β, IL-6, and IL-8. These findings were extended to a rat model where the microRNA-195 gene was introduced by adenovirus, and showed reduced neointimal formation in balloon-injured carotid arteries. Taken together, these data suggest that microRNA-195 may be vasculo-protective.
149. Hu C, Dandapat A, Mehta JL. Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway.
150. Cominacini L, Pasini AF, Garbin U, Davoli A, Tosetti ML, Campagnola M, et al. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J Biol Chem. 2000;275(17):12633-8. (Pubitemid 30241412)
151. Taye A, Saad AH, Kumar AH, Morawietz H. Effect of apocynin on NADPH oxidase-mediated oxidative stress-LOX-1-eNOS pathway in human endothelial cells exposed to high glucose. Eur J Pharmacol. 2010;627:42-8.
152. Tsai KL, Chen LH, Chiou SH, Chiou GY, Chen YC, Chou HY, et al. Coenzyme Q10 suppresses oxLDL-induced endothelial oxidative injuries by the modulation of LOX-1-mediated ROS generation via the AMPK/PKC/NADPH oxidase signaling pathway. Mol Nutr Food Res. 2011;55:S227-40.
153. Hu C, Dandapat A, Chen J, Liu Y, Hermonat PL, Carey RM, et al. Over-expression of angiotensin II type 2 receptor (agtr2) reduces atherogenesis and modulates LOX-1, endothelial nitric oxide synthase and heme-oxygenase-1 expression. Atherosclerosis. 2008;199:284-94.
154. Fukuda D, Enomoto S, Hirata Y, Nagai R, Sata M. The angiotensin receptor blocker, telmisartan, reduces and stabilizes atherosclerosis in ApoE and AT1aR double deficient mice. Biomed Pharmacother. 2010;64(10):712-7.